PMID- 1611472
OWN - NLM
STAT- MEDLINE
DCOM- 19920724
LR  - 20190613
IS  - 0006-8993 (Print)
IS  - 0006-8993 (Linking)
VI  - 569
IP  - 1
DP  - 1992 Jan 8
TI  - Angiotensin II evokes noradrenaline release from the paraventricular nucleus in 
      conscious rats.
PG  - 117-22
AB  - In vitro and in vivo experiments have provided indirect evidence that some of the 
      central actions of angiotensin II (ANG II) involve catecholaminergic pathways in 
      the brain. In this study in conscious rats we investigated the effect of 
      stimulation of periventricular ANG II receptors on blood pressure and on 
      catecholamine release (microdialysis and HPLC) from the paraventricular nucleus 
      (PVN), a hypothalamic area thought to be instrumental in the central pressor 
      responses to ANG II through the release of vasopressin into the blood. 
      Intracerebroventricular (i.c.v.) injections of pressor doses of ANG II (1 ng and 
      100 ng) led to significant dose-dependent increases of the noradrenaline (NA) 
      release in the PVN (1 ng: 30.95 +/- 6.01 to 47.38 +/- 6.79 pg/sample, P less than 
      or equal to 0.01; 100 ng: 32.93 +/- 5.38 to 73.18 +/- 11.4 pg/sample, P less than 
      or equal to 0.01). These changes coincided in extent and duration with the 
      respective pressor responses. A subpressor dose of ANG II (100 pg) did not 
      release catecholamines from the PVN. Dopamine (DA) and the NA and DA, metabolites 
      3,4-dihydroxyphenylethylglycol and 3,4-dihydroxyphenylacetic acid, were not 
      influenced by i.c.v. injections of ANG II at any dose. Pretreatment with the 
      novel non-peptide ANG II-AT 1 receptor antagonist DuP 753 (5 micrograms, i.c.v.) 
      abolished the effect of 100 ng ANG II on blood pressure and on NA release. Our 
      results show for the first time in vivo that stimulation of periventricular ANG 
      II-AT 1 receptors induces a selective NA release in the PVN. They further support 
      the hypothesis that ANG II engages a noradrenergic pathway in the PVN to release 
      vasopressin.
FAU - Stadler, T
AU  - Stadler T
AD  - Department of Pharmacology, University of Heidelberg, F.R.G.
FAU - Veltmar, A
AU  - Veltmar A
FAU - Qadri, F
AU  - Qadri F
FAU - Unger, T
AU  - Unger T
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - 102-32-9 (3,4-Dihydroxyphenylacetic Acid)
RN  - 11128-99-7 (Angiotensin II)
RN  - 534-82-7 (Methoxyhydroxyphenylglycol)
RN  - UEH9K539KJ (3,4-dihydroxyphenylglycol)
RN  - VTD58H1Z2X (Dopamine)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - 3,4-Dihydroxyphenylacetic Acid/metabolism
MH  - Analysis of Variance
MH  - Angiotensin II/administration & dosage/*pharmacology
MH  - Animals
MH  - Blood Pressure/*drug effects
MH  - Cerebral Ventricles/drug effects/*physiology
MH  - Dopamine/metabolism
MH  - Injections, Intraventricular
MH  - Kinetics
MH  - Male
MH  - Methoxyhydroxyphenylglycol/analogs & derivatives/metabolism
MH  - Norepinephrine/*metabolism
MH  - Paraventricular Hypothalamic Nucleus/drug effects/*physiology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Reference Values
MH  - Time Factors
EDAT- 1992/01/08 00:00
MHDA- 1992/01/08 00:01
CRDT- 1992/01/08 00:00
PHST- 1992/01/08 00:00 [pubmed]
PHST- 1992/01/08 00:01 [medline]
PHST- 1992/01/08 00:00 [entrez]
AID - 0006-8993(92)90377-L [pii]
AID - 10.1016/0006-8993(92)90377-l [doi]
PST - ppublish
SO  - Brain Res. 1992 Jan 8;569(1):117-22. doi: 10.1016/0006-8993(92)90377-l.